MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.
Multiple myeloma (MM) is due to the proliferation in the bone marrow of malignant plasma cells and accounts for about 10% of all hematological tumors. MM is the natural evolution of a monoclonal gammopathy of uncertain significance. Although the introduction of novel biological agents in the clinical practice has changed the natural history of the disease, MM remains incurable. MicroRNAs (miRNAs) are short non-coding RNAs that control cell functions through mRNA targeting. In the cancer setting, miRNAs have shown prognostic and predictive potentials. Several preclinical findings demonstrate their broad anticancer activities in various types of cancer, including MM. In this article, we provide an overview of the biology of miRNAs focusing on the role of miRNA deregulation in MM pathogenesis. These findings represent the basis to discuss the potential role of miRNAs as therapeutic agents against MM.
Marco
M
Rossi
Nicola
N
Amodio
Maria Teresa
MT
Di Martino
Pierosandro
P
Tagliaferri
Pierfrancesco
P
Tassone
Magna Graecia University, Viale Europa, 88100 Catanzaro, Italy. tassone@unicz.it.
William C
WC
Cho
D000818:Animals; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000187:drug effects / Q000378:metabolism*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics; D057170:Translational Research, Biomedical
D035683:MicroRNAs